Single-domain antibodies (VHH nanobodies) generated from immunised alpacas. The panel comprises H1-specific and broader group 1 cross-subtype neutralising nanobodies, including H5N1, interacting with conserved epitopes in the hemagglutinin stem region identified by deep mutational scanning.
Some of these nanobodies are featured in the following publications.
Gaiotto T, Hufton SE. Cross-Neutralising Nanobodies Bind to a Conserved Pocket in the Hemagglutinin Stem Region Identified Using Yeast Display and Deep Mutational Scanning. PLoS One. 2016 Oct 14;11(10):e0164296. doi: 10.1371/journal.pone.0164296.
Cheung CY, Dubey S, Hadrovic M, Ball CR, Ramage W, McDonald JU, Harvey R, Hufton SE, Engelhardt OG. Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies. Vaccines (Basel). 2022 Sep 5;10(9):1473. doi: 10.3390/vaccines10091473.
Hufton SE, Risley P, Ball CR, Major D, Engelhardt OG, Poole S. The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. PLoS One. 2014 Aug 1;9(8):e103294. doi: 10.1371/journal.pone.0103294.
Del Rosario JMM, Smith M, Zaki K, Risley P, Temperton N, Engelhardt OG, Collins M, Takeuchi Y, Hufton SE. Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity. Front Immunol. 2020 May 29;11:627. doi: 10.3389/fimmu.2020.00627.
For enquiries visit: Non-Exclusive Licensing Enquiry Form for Nanobodies